A Phase 2a, Randomized, Double-blind, Placebo-controlled, Parallel-group, Proof of Concept Study to Investigate Efficacy, Safety, Pharmacodynamics and Pharmacokinetics of ASP6294 in the Treatment of Female Subjects With Bladder Pain Syndrome/Interstitial Cystitis
Phase of Trial: Phase II
Latest Information Update: 04 Sep 2019
Price : $35 *
At a glance
- Drugs ASP 6294 (Primary)
- Indications Interstitial cystitis
- Focus Proof of concept; Therapeutic Use
- Acronyms SERENITY
- Sponsors Astellas Pharma Europe Ltd
- 08 May 2019 This trial has been completed in Czech Republic, according to European Clinical Trials Database.
- 19 Apr 2019 Status changed from active, no longer recruiting to completed.
- 17 Apr 2019 This trial has been completed in Latvia, according to European Clinical Trials Database.